Skip to main content

Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group

In brief

After 70, PSA screening overdiagnoses 10 to 13 cancers per death prevented in severely ill men

Two simulation models estimated that continued biennial screening with modern PSA and MRI approaches would cause 10 to 13 overdiagnoses for each prostate cancer death prevented among men with severe comorbidities aged 72 to 76. That ratio was at least twice the estimate for men without comorbidities, underscoring the need to weigh health and life expectancy when deciding when to stop screening.

Journal
Cancer (Q1)
Published
15 November 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Roman Gulati, Krithika Suresh, Sarah P Psutka, Jeremy M G Taylor, Lukas Owens, Alex Tsodikov, et al.
PMID
43018390
DOI
10.1002/cncr.70620

Why clinicians should know about it

  • Picked for Urology (paper of the day, 15 November 2026): Models screening benefits and overdiagnosis by age and comorbidity

Abstract

BACKGROUND: Prostate-specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis-diagnosis that would not occur during a man's lifetime without screening-particularly in older men and those with life-limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long-term harms and benefits have not been estimated. METHODS: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50-70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity-adjusted life tables. RESULTS: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI-targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7-3.1 at age 72 years to 4.5-5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6-10.2 at ages 72 to 11.3-12.6 at 76 years. CONCLUSIONS: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life-limiting comorbidities compared with age-matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.